Ben Holmes, Ph.D., is the CEO and Co-Founder of Nanochon. He holds a doctorate in biomedical engineering from The George Washington University, and an undergraduate engineering degree from the University of Virginia. He has extensive experience in tissue engineering and medical device development with both Nanochon and other early stage and commercial medical device companies. Holmes’ leadership at Nanochon’s has successfully gained the company dilutive and non-dilutive funding, as well as numerous awards, advancing their efforts to commercialize innovative cartilage repair technologies.
Nathan Castro
Chief Technology Officer
Bio
Dr. Nathan J. Castro is an experienced biomedical engineer and entrepreneur, specialized in leading the design, testing, regulatory approval and clinical translation of 3D printed medical devices. He has a PhD in Tissue Engineering and Regenerative Medicine from The George Washington University, a MS in Biomedical engineering from The University of Texas at El Paso, and a BA in Chemistry from The University of Texas at El Paso. As CTO and co-founder of Nanochon, Dr. Castro is engaged in early-stage development programs and leading them through all the disciplines of design, regulatory clearance, ISO13485 quality standards and intellectual property portfolio development to arrive at a commercial stage offering.
Matthew Scherer
Chief Financial Officer
Bio
Matthew Scherer is a seasoned capital markets professional experienced in strategic and financial advisory, M&A, private placement of debt and equity, and corporate development. He has been involved in mergers, acquisitions, and divestitures valued at over $6 billion, and debt and equity capital raises in excess of $15 billion. In addition, Matthew has completed public and private transactions ranging in size and scope from domestic middle market to complex cross border deals in a myriad of industries. Matthew received his M.B.A. from Fordham University Gabelli Graduate School of Business (Finance) and his B.B.A. from The George Washington University, with concentrations in Finance and Political Science.
Rachel Offenburg
Chief of Strategy
Bio
Rachel Offenburg, MBA serves as Nanochon’s Chief of Strategy where her day to day is focused on commercial strategy including marketing and communications. She has a Masters in Business Administration from the University of Virginia Darden School of Business, and an undergraduate degree in biology and business management from Emmanuel College. Rachel has extensive background in designing go to market strategies for early stage medical device and biotech startups, developed over the course of her career consulting at IQVIA, leading marketing teams at Bio-Rad Laboratories and managing data analytics platforms at Optum.
Clinical Team
Heather Neill
Chief Clinical Officer
Colleen Smith
Chief Project Manager
BOARD OF DIRECTORS
Robert Creeden
Managing Director, UVA LVG Seed Fund and New Ventures
R. Sean Churchill, MD, MBA
Managing Director, Managing Director of cultivate(MD)
Nicholas Pachuda
Peptilogics, Senior Vice President, Portfolio & Development